SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galin...
January 24 2018 - 8:55AM
SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (SELLAS) today
announced that an abstract highlighting the detailed description of
antigen-specific immune responses and correlation thereof with
clinical effects over time has been accepted for oral
presentation at the 2018 European Society for Blood and Marrow
Transplantation (EBMT) 44th Annual Meeting taking place March 18-21
in Lisbon, Portugal.
“The abstract to be presented at the EBMT Conference highlights
the depth of our clinical program exploring the potential of
GPS as an innovative immunotherapeutic for multiple cancer
types,” said Angelos M. Stergiou, MD, ScD h.c., President and CEO
of SELLAS. “There has been great interest in immuno-oncology
approaches for the treatment of MM and GPS offers an exciting
opportunity by directly immunizing the host against a key immune
target in multiple myeloma, namely WT1, particularly in view of
strong differentiating attributes of our hetereoclitic
immunotherapeutic as well as the other indications we are carefully
pursuing.”
Multiple myeloma (MM) patients with high-risk cytogenetics at
baseline who also remain positive for minimal residual disease
post-frontline autologous stem cell transplantation continue to
experience poor clinical outcomes, despite maintenance with
immunomodulatory drugs, such as lenalidomide. This is a population
segment that represents approximately 15-20% of first-line MM
patients. In previous reports, such patients immunized with GPS in
a Phase 2 study (n=18) experienced a median progression-free
survival of 23.6 months and an 18 month overall survival of
88%.
The presentation at the EBMT Conference will entail detailed
correlative analyses between clinical benefit, as reflected by the
rate of achievement of complete response/very good partial
response, per International Myeloma Working Group criteria, and
antigen-specific immuno-responses of the complete dataset from this
Phase 2 study.
Details for the presentation are as follows:
- Title: Clinical Benefit after Galinpepimut-S
(GPS), a WT1 Immunotherapeutic, Correlates With Antigen-Specific
Immune Responses in High-Risk Multiple Myeloma: Complete Analysis
of the Phase 2 GPS Maintenance Study.
- Presenter: Guenther Koehne, MD, PhD, Miami
Cancer Institute, Baptist Health South Florida
- Session: Oral Session 4 – Multiple
Myeloma; Room 5B
- Abstract Number: A-947-0029-01047
- Date/Time: March 19, 2018, 3:50 p.m WET/ 10:50
a.m. EST
- Location: Centro de Congressos de Lisboa /
Lisbon Congress Centre (LCC), Room 5B
The presentation will be made available on the Presentations
section of Sellas’ website at
www.sellaslifesciences.com/publications immediately following the
presentation.
About galinpepimut-S (GPS)
GPS is a heteroclitic multivalent, multi-peptide cancer
immunotherapeutic agent composed of four peptides, addressing
over 20 epitopes, and derived from the WT1 protein, which has been
ranked by the National Cancer Institute as a top priority among
cancer antigens for immunotherapy. Importantly, because the WT1
antigen is over-expressed in many malignancies, and is not found in
most normal tissues, GPS has the potential to be a broad
immunotherapy, effective across a multitude of diverse cancer types
and patient populations.
About SELLAS Life Sciences Group
SELLAS is a development-stage biopharmaceutical company focused
on novel cancer immunotherapeutics for a broad range of cancer
indications. SELLAS' lead product candidate, galinpepimut-S (GPS),
is licensed from Memorial Sloan Kettering Cancer Center and targets
the Wilms Tumor 1 (WT1) protein, which is present in an array of
tumor types. GPS has potential as a monotherapy or in combination
to address a broad spectrum of hematologic malignancies and solid
tumor indications. GPS has Phase 3 clinical trials planned (pending
funding availability) for two indications, acute myeloid leukemia
(AML) and malignant pleural mesotheliomia (MPM). It is also in
development as a potential treatment for multiple myeloma and
ovarian cancer. SELLAS plans to study GPS in up to four additional
indications. SELLAS recently received Orphan Drug designations from
the U.S. Food & Drug Administration (FDA), as well as the
European Medicines Agency, for GPS in AML and MPM; GPS also
received Fast Track designation for AML and MPM from the FDA.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to the
presentation of data and the ability to further develop
galinpepimut-S for a broad range of cancer indications. These
forward-looking statements are based on current plans, objectives,
estimates, expectations and intentions, and inherently involve
significant risks and uncertainties. Actual results and the timing
of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with cancer immunotherapy product
development and clinical success thereof, attaining and maintenance
of adequate IP protection, the uncertainty of regulatory approval,
and other risks and uncertainties affecting SELLAS and its
development programs. Risks and uncertainties facing SELLAS are
more fully described in SELLAS’s filings with the Securities and
Exchange Commission, particularly in the section titled “Risk
Factors.” Other risks and uncertainties of which SELLAS is not
currently aware may also affect SELLAS’ forward-looking statements
and may cause actual results and the timing of events to differ
materially from those anticipated. The forward-looking statements
herein are made only as of the date hereof. SELLAS undertakes no
obligation to update or supplement any forward-looking statements
to reflect actual results, new information, future events, changes
in its expectations or other circumstances that exist after the
date as of which the forward-looking statements were made.
Investor Contact:Will O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
David Moser, JDSELLAS Life Sciences
Group813-864-2571info@sellaslife.com
Source: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024